Cadmium and proliferation in human uterine leiomyoma cells: Evidence of a role for EGFR/MAPK pathways but not classical estrogen receptor pathways

Environmental Health Perspectives

Volumn 123, Issue 4, 2015, Pages 331-336

  Gao, Xiaohua ^a   Yu, Linda ^a   Moore, Alicia B ^a   Kissling, Grace E ^b   Waalkes, Michael P ^c   Dixon, Darlene ^a  

^a Division of the NTP   (United States)

^b Department of Health and Human Services   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL) CHROMONE; 4 (3 CHLOROANILINO) 6, 7 DIMETHOXYQUINAZOLINE; CADMIUM; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; COMPETITIVE BINDING ASSAY; CONTROLLED STUDY; ESTROGEN BINDING; ESTROGEN RESPONSIVE ELEMENT; FEMALE; GENE CONTROL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; LUCIFERASE ASSAY; MTS ASSAY; MYOMETRIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UTERUS MYOMA; WESTERN BLOTTING; DRUG EFFECTS; LEIOMYOMA; METABOLISM; PATHOLOGY; TUMOR CELL LINE; UTERUS CANCER;

RATTUS;

CADMIUM; CELL LINE, TUMOR; CELL PROLIFERATION; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; LEIOMYOMA; MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; UTERINE NEOPLASMS;

EID: 84961289184     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1408234     Document Type: Article

References (50)

1. Agency for Toxic Substances and Disease Registry. 2012. Toxicological Profile for Cadmium. Available: http://www.atsdr.cdc.gov/toxprofiles/tp5.pdf [accessed 10 October 2014].
2. Ali I, Damdimopoulou P, Stenius U, Adamsson A, Mäkelä SI, Åkesson A, et al. 2012. Cadmium- induced effects on cellular signaling pathways in the liver of transgenic estrogen reporter mice. Toxicol Sci 127:66–75.
3. Ali I, Penttinen-Damdimopoulou PE, Mäkelä SI, Berglund M, Stenius U, Åkesson A, et al. 2010. Estrogen-like effects of cadmium in vivo do not appear to be mediated via the classical estrogen receptor transcriptional pathway. Environ Health Perspect 118:1389–1394; doi:10.1289/ehp.1001967.
4. Benbrahim-Tallaa L, Tokar EJ, Diwan BA, Dill AL, Coppin JF, Waalkes MP. 2009. Cadmium malig-nantly transforms normal human breast epithelial cells into a basal-like phenotype. Environ Health Perspect 117:1847–1852; doi:10.1289/ehp.0900999.
5. Carney SA, Tahara H, Swartz CD, Risinger JI, He H, Moore AB, et al. 2002. Immortalization of human uterine leiomyoma and myometrial cell lines after induction of telomerase activity: molecular and phenotypic characteristics. Lab Invest 82:719–728.
6. Carpenter RL, Jiang BH. 2013. Roles of EGFR, PI3K, AKT, and mTOR in heavy metal-induced cancer. Curr Cancer Drug Targets 13:252–266.
7. Ciardiello F, Tortora G. 2008. EGFR antagonists in cancer treatment. N Engl J Med 358:1160–1174.
8. Ciarmela P, Islam MS, Reis FM, Gray PC, Bloise E, Petraglia F, et al. 2011. Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. Hum Reprod Update 17:772–790.
9. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D. 2006. Activation of mitogen-activated protein kinase in estrogen receptor α-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor α-negative human breast tumors. Cancer Res 66:3903–3911.
10. Dhillon AS, Hagan S, Rath O, Kolch W. 2007. Map kinase signalling pathways in cancer. Oncogene 26:3279–3290.
11. Di X, Yu L, Moore AB, Castro L, Zheng X, Hermon T, et al. 2008. A low concentration of genistein induces estrogen receptor-alpha and insulin-like growth factor-I receptor interactions and prolifera tion in uterine leiomyoma cells. Hum Reprod 23:1873–1883.
12. Gao X, Yu L, Castro L, Tucker CJ, Moore AB, Xiao H, et al. 2012. An essential role of p27 downregula-tion in fenvalerate-induced cell growth in human uterine leiomyoma and smooth muscle cells. Am J Physiol Endocrinol Metab 303:E1025–E1035.
13. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, et al. 2007. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 87:905–931.
14. Henson MC, Chedrese PJ. 2004. Endocrine disruption by cadmium, a common environmental toxicant with paradoxical effects on reproduction. Exp Biol Med (Maywood) 229:383–392.
15. Höfer N, Diel P, Wittsiepe J, Wilhelm M, Kluxen FM, Degen GH. 2010. Investigations on the estrogenic activity of the metallohormone cadmium in the rat intestine. Arch Toxicol 84:541–552.
16. International Agency for Research on Cancer. 2012. Cadmium and cadmium compounds. IARC Monogr Eval Carcinog Risk Hum 100C:121–145.Available: http://monographs.iarc.fr/ENG/Monographs/vol100C/mono100C-8.pdf [accessed 10 October 2014].
17. Isidori M, Cangiano M, Palermo FA, Parrella A. 2010. E-screen and vitellogenin assay for the detec-tion of the estrogenic activity of alkylphenols and trace elements. Comp Biochem Physiol C Toxicol Pharmacol 152:51–56.
18. Jackson LW, Zullo MD, Goldberg JM. 2008. The asso-ciation between heavy metals, endometriosis and uterine myomas among premenopausal women: National Health and Nutrition Examination Survey 1999–2002. Hum Reprod 23:679–687.
19. Jiang Y, Suo G, Sadarangani A, Cowan B, Wang JY. 2010. Expression profiling of protein tyrosine kinases and their ligand activators in leiomyoma uteri. Syst Biol Reprod Med 56:318–326.
20. Jing Y, Liu LZ, Jiang Y, Zhu Y, Guo NL, Barnett J, et al. 2012. Cadmium increases HIF-1 and VEGF expres-sion through ROS, ERK, and AKT signaling pathways and induces malignant transformation of human bronchial epithelial cells. Toxicol Sci 125:10–19.
21. Johnson MD, Kenney N, Stoica A, Hilakivi-Clarke L, Singh B, Chepko G, et al. 2003. Cadmium mimics the in vivo effects of estrogen in the uterus and mammary gland. Nat Med 9:1081–1084.
22. Julin B, Wolk A, Bergkvist L, Bottai M, Åkesson A. 2012. Dietary cadmium exposure and risk of post-menopausal breast cancer: a population-based prospective cohort study. Cancer Res 72:1459–1466.
23. Kippler M, Tofail F, Gardner R, Rahman A, Hamadani JD, Bottai M, et al. 2012. Maternal cadmium exposure during pregnancy and size at birth: a prospective cohort study. Environ Health Perspect 120:284–289; doi:10.1289/ehp.1103711.
24. Kluxen FM, Höfer N, Kretzschmar G, Degen GH, Diel P. 2012. Cadmium modulates expression of aryl hydrocarbon receptor-associated genes in rat uterus by interaction with the estrogen receptor. Arch Toxicol 86:591–601.
25. Kriegel AM, Soliman AS, Zhang Q, El-Ghawalby N, Ezzat F, Soultan A, et al. 2006. Serum cadmium levels in pancreatic cancer patients from the East Nile Delta region of Egypt. Environ Health Perspect 114:113–119; doi:10.1289/ehp.8035.
26. Kundu S, Sengupta S, Bhattacharyya A. 2011. EGFR upregulates inflammatory and proliferative responses in human lung adenocarcinoma cell line (A549), induced by lower dose of cadmium chloride. Inhal Toxicol 23:339–348.
27. Leygue E, Murphy LC. 2013. A bi-faceted role of estrogen receptor β in breast cancer. Endocr Relat Cancer 20:R127–R139.
28. Lienesch LA, Dumont JN, Bantle JA. 2000. The effect of cadmium on oogenesis in Xenopus laevis. Chemosphere 41:1651–1658.
29. Liu Z, Yu X, Shaikh ZA. 2008. Rapid activation of ERK1/2 and AKT in human breast cancer cells by cadmium. Toxicol Appl Pharmacol 228:286–294.
30. Martinez Flores K, Uribe Marin BC, Souza Arroyo V, Bucio Ortiz L, López Reyes A, Gómez-Quiroz LE, et al. 2013. Hepatocytes display a compensatory survival response against cadmium toxicity by a mechanism mediated by EGFR and Src. Toxicol In Vitro 27:1031–1042.
31. McKay MM, Morrison DK. 2007. Integrating signals from RTKs to ERK/MAPK. Oncogene 26:3113–3121.
32. Nampoothiri LP, Agarwal A, Gupta S. 2007. Effect of co-exposure to lead and cadmium on antioxidant status in rat ovarian granulose cells. Arch Toxicol 81:145–150.
33. Nasiadek M, Krawczyk T, Sapota A. 2005. Tissue levels of cadmium and trace elements in patients with myoma and uterine cancer. Hum Exp Toxicol 24:623–630.
34. Nasiadek M, Swiatkowska E, Nowinska A, Krawczyk T, Wilczynski JR, Sapota A. 2011. The effect of cadmium on steroid hormones and their recep-tors in women with uterine myomas. Arch Environ Contam Toxicol 60:734–741.
35. NHANES (National Health and Nutrition Examination Survey). 2011. 2009–2010 Data Documentation, Codebook, and Frequencies. Blood Cadmium, Lead, and Total Mercury (PbCd_F). Available: http://www.cdc.gov/nchs/nhanes/nhanes2009-2010/pbcd_f.htm [accessed 10 October 2014].
36. Olympio KP, Gonçalves C, Günther WM, Bechara EJ. 2009. Neurotoxicity and aggressiveness triggered by low-level lead in children: a review. Rev Panam Salud Publica 26:266–275.
37. Osborne CK, Schiff R. 2005. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 23:1616–1622.
38. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. 2004. EGFR mutations in lung cancer: corre-lation with clinical response to gefitinib therapy. Science 304:1497–1500.
39. Pollack AZ, Schisterman EF, Goldman LR, Mumford SL, Albert PS, Jones RL, et al. 2011. Cadmium, lead, and mercury in relation to reproductive hormones and anovulation in premenopausal women. Environ Health Perspect 119:1156–1161; doi:10.1289/ehp.1003284.
40. Qu W, Tokar EJ, Kim AJ, Bell MW, Waalkes MP. 2012. Chronic cadmium exposure in vitro causes acquisition of multiple tumor cell characteristics in human pancreatic epithelial cells. Environ Health Perspect 120:1265–1271; doi:10.1289/ehp.1205082.
41. Shimomura Y, Matsuo H, Samoto T, Maruo T. 1998. Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab 83:2192–2198.
42. Siewit CL, Gengler B, Vegas E, Puckett R, Louie MC. 2010. Cadmium promotes breast cancer cell prolif-eration by potentiating the interaction between ERα and c-Jun. Mol Endocrinol 24:981–992.
43. Silva E, Lopez-Espinosa MJ, Molina-Molina JM, Fernández M, Olea N, Kortenkamp A. 2006. Lack of activity of cadmium in in vitro estrogenicity assays. Toxicol Appl Pharmacol 216:20–28.
44. Verougstraete V, Lison D, Hotz P. 2003. Cadmium, lung and prostate cancer: a systematic review of recent epidemiological data. J Toxicol Environ Health B Crit Rev 6:227–255.
45. Wilson VS, Bobseine K, Gray LE Jr. 2004. Development and characterization of a cell line that stably expresses an estrogen-responsive luciferase reporter for the detection of estrogen receptor agonist and antagonists. Toxicol Sci 81:69–77.
46. Youn CK, Kim SH, Lee DY, Song SH, Chang IY, Hyun JW, et al. 2005. Cadmium down-regulates human OGG1 through suppression of Sp1 activity. J Biol Chem 280:25185–25195.
47. Yu L, Moore AB, Dixon D. 2010. Receptor tyrosine kinases and their hormonal regulation in uterine leiomyoma. Semin Reprod Med 28(3):250–259.
48. Yu L, Saile K, Swartz CD, He H, Zheng X, Kissling GE, et al. 2008. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway acti-vation in human uterine leiomyomas. Mol Med 14:264–275.
49. Zang Y, Odwin-Dacosta S, Yager JD. 2009. Effects of cadmium on estrogen receptor mediated signaling and estrogen induced DNA synthesis in T47D human breast cancer cells. Toxicol Lett 184:134–138.
50. Zhang M, He Z, Wen L, Wu J, Yuan L, Lu Y, et al. 2010. Cadmium suppresses the proliferation of piglet Sertoli cells and causes their DNA damage, cell apoptosis and aberrant ultrastructure. Reprod Biol Endocrinol 8:97; doi:10.1186/1477-7827-8-97.